MLYS•benzinga•
Mineralys Therapeutics To Present Data From Pivotal Phase 3 Launch-HTN Trial Evaluating Efficacy And Safety Of Lorundrostat For Treatment Of uHTN Or rHTN In Late-Breaking Clinical Trials Session At ESH 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga